idanosine is a purine nucleoside analog that is indicated for the treatment of human immunodeficiency virus (HIV) infection. It has been administered orally with antacids to protect against acid-induced hydrolysis in the stomach. 1 Formulations of didanosine that are currently available as buffered products or are intended to be used with buffer include the buffered powder for oral solution, chewable/dispersible buffered tablet, and pediatric nonbuffered powder for oral solution. The presence of buffers in a formulation can result in absorption-based interactions with drugs whose bioavailability is influenced by antacids and has been associated with gastrointestinal side effects. To eliminate the need for using buffers in the didanosine formulations, an enteric-coated bead formulation of didanosine was developed and approved for marketing in the United States and Europe. The encapsulated enteric-coated beads lack any significant pharmacokinetic interaction with ciprofloxacin, indinavir, and ketoconazole, with each drug representative of a broader class of agents whose bioavailability is markedly influenced by the presence of antacids in the formulation.
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Didanosine is an acid labile drug and hence has been given with buffering agents. To avoid the need for concurrent administration with antacids, an encapsulated enteric-coated bead formulation of didanosine was developed. The objective of this study was to assess the bioequivalence of the encapsulated enteric-coated beads compared to the buffered tablet. Two separate open-label, randomized, two-way crossover studies were conducted, one in healthy subjects and the other in HIV-infected subjects (with CD4 cell counts > 200 cells/mm 3

). All subjects received a 400-mg dose of the buffered tablet (reference formulation) and the encapsulated enteric-coated beads (test formulation
)
METHODS
Study Design
Two separate clinical studies were conducted, one in normal healthy volunteers and one in HIV-infected subjects, to assess bioequivalence between the encapsulated enteric-coated beads and the buffered tablet formulation. Both studies were conducted as open-label, single-dose, randomized, two-way crossover studies with treatments in each study as follows: Treatment A, 2 × 200 mg buffered tablet (reference), and Treatment B, 1 × 400 mg encapsulated enteric-coated beads (test). The washout period between treatments was at least 72 hours. Both treatments were given after an overnight fast of at least 10 hours, which was maintained for 4 hours after dose. Water intake was allowed during the fasting period except for 1 hour before and 2 hours after dosing, when water intake was restricted to that necessary for dosing. Treatments were given with about 240 ml of room temperature tap water.
Male or female subjects, 18 to 50 years of age, and a minimum body weight of 60 kg were enrolled in both studies. Female subjects of childbearing potential had a confirmed negative pregnancy test 72 hours prior to the study and had to be using an effective, nonhormonal method of birth control during the course of the study. Subjects were in good health as determined by medical/ laboratory tests conducted 3 weeks prior to study start and by physical examination conducted on the morning of the first dose of the study. In addition, the following inclusion criteria were applied for HIV-infected subjects: HIV seropositive as confirmed by Western blot, CD4 cell count ≥ 200 cells/mm 3 , serum creatinine ≤ 1.5 times the upper limit of normal, total serum lipase ≤ 1.4 times the upper limit of normal, and liver enzymes (SGOT and SGPT) < 5 times the upper limit of normal within 3 weeks prior to starting the study.
Clinical evaluations, including laboratory tests, were performed during screening and prior to discharge to assess safety and tolerance. Safety assessment was done by monitoring the occurrence of adverse events (AEs), physical examinations, vital signs, clinical laboratory results, and electrocardiograms from prestudy screen through discharge. Written informed consent was obtained from subjects before the start of each study.
Plasma Collection and Analyses
Blood samples (about 3 ml) were collected at the following time intervals: predose and 0.17, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.33, 3.67, 4, 4.5, 5, 6, 8, 10, and 12 hours after dosing. Immediately after collection, each blood sample was gently inverted a few times for complete mixing with the anticoagulant (heparin) and then placed in chipped ice. Plasma was separated within 1 hour of blood collection by centrifugation and stored at -20°C until analyzed for didanosine concentrations.
Plasma levels of didanosine were determined using a validated radioimmunoassay (RIA). Briefly, validation included an evaluation of assay specificity, accuracy, precision, and stability of the antibody-bound analyte. The RIA involved the addition of tritiated didanosine (diluted into phosphate-buffered saline containing rabbit IgG) to 10 µl of the heparinized plasma sample (heated for 3 h at 56°C to inactivate HIV in the case of HIV-infected subjects). A volume of rabbit antididanosine antibody was added, followed by incubation at room temperature for 60 minutes. Rabbit IgG immunoprecipitation reagent was added at the completion of the incubation period. After centrifugation, the supernatant was carefully decanted. The pellets remaining in the tubes were reconstituted in dilute hydrochloric acid solution, and an aliquot was transferred to a vial containing liquid scintillation cocktail. An analytical run consisted of standards (prepared at seven concentrations over the range of 3 to 200 ng/ml and analyzed in duplicate), quality control samples (three different concentrations, analyzed in triplicate), and duplicate study samples. Standard curves were constructed using a four-parameter logistic regression model. 3 Individual runs were considered acceptable if they met a priori defined standard acceptance criteria.
Pharmacokinetic Analyses
The plasma concentration-time data were analyzed by a noncompartmental method. 4 The peak plasma concentration (C max ) and the time to peak plasma concentration (t max ) were obtained from experimental observations. Using no weighting factor, the terminal log-linear phase of the plasma concentration-time curve was identified by least squares linear regression of at least three data points, which yielded a minimum mean square error. The half-life of the terminal log-linear phase (t 1/2 ) was calculated as 0.693/K, where K is the absolute value of the slope of the terminal log-linear phase. The area under the plasma concentration-time curve from 0 to infinity (AUC ∞ ) was determined by summing the areas from time 0 to the time of last measured concentration, calculated by using conventional trapezoidal and log-trapezoidal methods and the extrapolated area. The extrapolated area was determined by dividing the final concentration by the slope of the terminal log-linear phase.
Statistical Analyses
Bioequivalence with respect to the primary study parameters C max and AUC ∞ was assessed by the two one-sided test procedure applied to the results of the analysis of the log-transformed values. The factors in the analysis were treatment sequences, subject within sequence, period, and treatment. The F-statistic for sequence effects used the Type I sum of squares for sequence in the numerator and the Type I sum of squares for subjects within sequence as the denominator. The F-statistic for period used the Type I sum of squares in the numerator and the Type I sum of squares for residual error as its denominator. The F-statistic for treatment effects used the corresponding Type III sum of squares in the numerator and the sum of squares for residual error as its denominator. For each parameter, the confidence interval (CI) for the difference between the least squares means on the natural log scale was converted to a CI for the ratio of means on the original scale. The 90% CI of the ratio of the geometric means of log-transformed C max and AUC ∞ values was used to assess bioequivalence between the two formulations using the equivalence interval of 0.80 and 1.25. Only descriptive statistics were done for t max and t 1/2 . All statistical analyses were carried out using SAS/STAT ® , version 6.11.
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RESULTS
Subject Enrollment
In the normal healthy volunteer study, 47 subjects were enrolled, 46 of whom completed the study as planned. One healthy subject gagged immediately after receiving the buffered tablet due to the unpleasant taste of the buffer and was unable to swallow the study drug; this subject was discontinued from the study by the investigator. In the HIV-infected study, a total of 32 subjects were enrolled, of whom 30 subjects completed the study as planned; 2 subjects discontinued from the study at their own request after receiving one treatment. The demographic parameters for subjects in both studies are given in Table I .
Sample Analyses
For the analyses of the plasma samples in both studies, the standard curves were linear (R 2 ≥ 0.994) over the concentration range of 3 to 200 ng/ml. Furthermore, the mean predicted concentrations of the shipping and analytical quality control samples were within 4.1% of their nominal values; between-run and within-run variabilities were within 10.3% relative standard deviation. The standard curve and quality control data indi- cated that the plasma assay method was precise and accurate and that didanosine was stable in the plasma samples in both studies during shipment and storage.
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Pharmacokinetics of Didanosine
The plasma concentration-time profiles for didanosine in healthy and HIV-infected subjects are given in Figures 1 and 2 , respectively; the pharmacokinetic parameters are presented in Tables II and III , respectively. The absorption of didanosine was rapid following administration of the buffered tablet (t max = 0.67 h) but was prolonged for the enteric-coated beads in both healthy subjects (t max = 2.33 h) and HIV-infected subjects (t max = 2.0 h) (Tables II and III) . Inspection of the individual plasma concentration-time profiles suggested a lag time of approximately 20 minutes for the entericcoated beads. The mean half-life of didanosine was similar between treatments and ranged between 1.60 and 1.70 hours across healthy and HIV-infected subjects. The relative bioavailability point estimates and 90% CI in healthy and HIV-infected subjects are given in Table IV. The geometric mean C max values were lower by 42% and 36% for the enteric-coated beads relative to the buffered tablet in healthy and HIV-infected subjects, respectively. In both study populations, the 90% CI for C max fell below the prespecified lower limits, suggesting that the bioequivalence requirement for C max was not met. The point estimates for the AUC ∞ values for the enteric-coated beads compared to the buffered tablet were reasonably close to unity in healthy and HIV-infected subjects, and the 90% CI fell entirely within the prespecified limits, indicating that the requirement for bioequivalence was satisfied for AUC ∞ .
Safety Results
In healthy volunteers, 14 and 13 AEs (in 11 and 10 subjects, respectively) were reported after administration of the buffered tablet and the enteric-coated beads, respectively. The most frequent AEs were headache and nausea. Other reported events included diarrhea, dyspepsia, vomiting, agitation, anxiety, dizziness, pharyngitis, dysmenorrhea, and urinary tract infection. The intensity of all AEs was rated as mild or moderate, and all events resolved without treatment or medication. In HIV-infected subjects, 3 and 5 AEs (in 3 and 2 subjects, respectively) were reported after administration of the buffered tablet and the enteric-coated beads, respectively. The most frequently reported AE was headache. Other AEs reported in HIV-infected subjects were pain, fever, peripheral edema, and dizziness. These 
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. Mean (SD) plasma concentrations of didanosine after administration of the buffered tablet and encapsulated enteric-coated beads in healthy subjects (n = 46).
AEs did not require any treatment or medication and were resolved prior to discharge. In both studies, there were no serious AEs. Furthermore, no clinically meaningful changes were apparent in vital signs and clinical laboratory tests of the subjects in either study. In summary, a single dose of 400 mg of didanosine given as a buffered tablet or the encapsulated enteric-coated bead formulation was well tolerated by normal healthy volunteers and by HIV-infected subjects.
DISCUSSION
Didanosine is labile in an acidic environment; therefore, the drug has been administered orally with buffers or antacids to protect it from acid-induced hydrolysis in the stomach. Administration of didanosine as an enteric-coated formulation protects the drug from degradation in the stomach, eliminating the need for concomitant dosing with antacid. This should lead to improved tolerability and patient compliance for didanosine and eliminate any drug interactions due to the presence of the antacids in the current formulation. The data from these studies in normal healthy volunteers and HIV-infected subjects demonstrate that the encapsulated enteric-coated bead formulation of didanosine was bioequivalent with respect to AUC, but not C max , to the buffered tablet of didanosine. These data indicate that the protection against gastric pH offered by the enteric coating was similar to that achieved with the antacid, resulting in equivalent exposure to didanosine. However, additional time was required for the plasma concentrations of didanosine to peak after the enteric-coated bead formulation was administered relative to the buffered tablet. This shift in t max can be explained by the time necessary for gastric emptying and for the dissolution of the enteric coat in the upper small intestine. Inspection of the individual subject concentration versus time profiles suggested that the time involved for these processes for the enteric formulation resulted in a lag time of at least 20 minutes in both healthy and HIV-infected subjects. The rate of absorption was also slower as indicated by lower C max values for the enteric-coated beads. However, at sampling times beyond the occurrence of t max of the enteric formulations, the average didanosine plasma concentration for the enteric-coated beads was 1.4-to 3.2-fold and 1.4-to 2.6-fold greater than the corresponding value for the tablet formulation in healthy and HIVinfected subjects, respectively. Since the absorption of didanosine occurs throughout the small intestine a. C max (ng/ml) and AUC ∞ (h•ng/ml) were analyzed on a log scale.
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based on reported scintigraphy evaluations, 6 intersubject variability in gastrointestinal transit appears to have a minimal effect on the extent of absorption from the enteric-coated formulation but is reflected in the variability in C max and t max values. The comparability of the half-life of didanosine for the enteric-coated beads and buffered tablet formulations indicates that overall absorption from the enteric-coated beads is not prolonged in either healthy subjects or those infected with HIV, an observation that is consistent with the scintigraphy data suggestive of minimal colonic absorption. 6 By nature of these single-dose assessments used for bioequivalence studies, it was not possible to assess the relationship between plasma pharmacokinetics and markers of efficacy such as viral loads in HIV-infected patients. Importantly, didanosine needs to be converted intracellularly to its active moiety, dideoxyadenosine triphosphate (ddATP), which inhibits viral replication. 7, 8 Hence, the relationship between plasma pharmacokinetics and viral load is not anticipated to be clinically meaningful. Due to the lack of availability of a sensitive analytical assay for the quantitation of ddATP at the time these studies were conducted, it was not feasible to assess ddATP levels and correlate these to surrogate markers of efficacy. It should be noted that the average steady-state plasma concentration of didanosine, derived by dividing the total daily AUC by 24 hours, has been shown to strongly correlate with markers of antiviral efficacy in adults with AIDS or AIDS-related complex, and AUC has been correlated with declines in p24 antigen levels and improvement in intelligence quotient scores in pediatric patients. 9, 10 Equivalence in AUC for the enteric-coated and buffered tablet formulations of didanosine means that the same average steady-state plasma concentrations of didanosine may be maintained.
In lieu of pharmacokinetic-pharmacodynamic correlation, the regulatory approval of the enteric-coated bead formulation of didanosine was based on clinical safety and efficacy studies. In an early clinical study that compared the antiviral activity of triple-combination regimens containing stavudine, nelfinavir, and either the encapsulated enteric-coated beads or the buffered tablet formulation of didanosine (400 mg, once daily), comparable antiviral activity, as measured by the change in HIV RNA levels from baseline through 48 weeks, was observed. 11 However, due to the high subject dropout rate in this study, the authors were unable to make definitive conclusions about comparability in efficacy between the two formulations. Nonetheless, these data are suggestive that changes in C max with the enteric formulation relative to the buffered tablet are unlikely to compromise antiviral efficacy.
A prospective, open-label, randomized, two-arm, Phase III study was designed to compare the antiviral activity and tolerability of the encapsulated entericcoated bead formulation of didanosine (400 mg, once daily) in combination with stavudine and nelfinavir with that of the combination of combivir and nelfinavir. A total of 511 HIV-infected subjects were randomized 1:1 to the two treatment arms. Subjects were eligible to participate if they had received limited or no other antiretroviral therapy, had a CD4 cell count ≥ 200 cells/mm 3 , and had plasma viral load of ≥ 2000 HIV RNA copies/ml.
12 Dosing was to be for a period of at least 48 weeks after enrollment of the last subject. The results from this study unequivocally indicated that there were no differences in HIV RNA responses over 48 weeks between the two regimens. These data provide strong evidence supporting the use of the entericcoated bead formulation given once daily in highly active antiretroviral therapy (HAART).
For both formulations, there was a trend toward lower exposures of didanosine in HIV-infected subjects compared to healthy volunteers. Considering the variability in the kinetics of didanosine and, importantly, since efficacy studies with didanosine were conducted in the HIV-infected population, it is unclear if these differences are relevant. It should be noted that related nucleoside analogues such as zidovudine and lamivudine demonstrate pharmacokinetic properties that are similar between normal healthy subjects and HIV-seropositive patients. 13, 14 In conclusion, the encapsulated enteric-coated bead formulation of didanosine is equivalent to the buffered tablet in the extent of exposure but differs in the rate of absorption in healthy volunteers and in HIV-infected subjects. These data, in conjunction with clinical efficacy, provide a strong rationale for the use of the encapsulated enteric-coated bead formulation of didanosine in the management of HIV infection.
